Prenatal Programming of Metabolic Syndrome in the Common Marmoset Is Associated With Increased Expression of 11β-Hydroxysteroid Dehydrogenase Type 1

被引:50
|
作者
Nyirenda, Moffat J. [1 ]
Carter, Roderick [1 ]
Tang, Justin I. [1 ]
de Vries, Annick [1 ]
Schlumbohm, Christina [2 ]
Hillier, Stephen G. [3 ]
Streit, Frank [4 ]
Oellerich, Michael [4 ]
Armstrong, Victor W. [4 ]
Fuchs, Eberhard [2 ]
Seckl, Jonathan R. [1 ]
机构
[1] Univ Edinburgh, Endocrinol Unit, Queens Med Res Inst, Edinburgh EH8 9YL, Midlothian, Scotland
[2] Leibniz Inst Primate Res, Clin Neurobiol Lab, German Primate Ctr, Gottingen, Germany
[3] Univ Edinburgh, MRC, Reprod Sci Unit, Queens Med Res Inst, Edinburgh EH8 9YL, Midlothian, Scotland
[4] Univ Gottingen, Dept Clin Chem, Gottingen, Germany
关键词
TISSUE-SPECIFIC DYSREGULATION; GLUCOCORTICOID METABOLISM; INSULIN-RESISTANCE; GLUCOSE-METABOLISM; ADIPOSE-TISSUE; OBESITY; CORTISOL; RATS; DISEASE; MICE;
D O I
10.2337/db09-0873
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE-Recent studies in humans and animal models of obesity have shown increased adipose tissue activity of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1), which amplifies local I issue glucocorticoid concentrations. The reasons for this 11 beta-HSD1 dystegulation are unknown. Here, we tested whether 11 beta-HSD1 expression, like the metabolic syndrome, is "programmed" by prenatal environmental events in a nonhuman primate model, the common marmoset monkey. RESEARCH DESIGN AND METHODS-We used a "fetal programming" paradigm where brief antenatal exposure to glucocorticoids leads to the metabolic syndrome in the offspring. Pregnant marmosets were given the synthetic glucocorticoid dexamethasone orally for 1 week in either early or late gestation, or they were given vehicle. Tissue 11 beta-HSD1 and glucocorticoid receptor mRNA expression were examined in the offspring at 4 and 24 months of age. RESULTS-Prenatal dexamethasone administration, selectively during late gestation, resulted in early and persistent elevations in 11 beta-HSD1 mRNA expression and activity in the liver, pancreas, and subcutaneous-but not visceral-fat. The increase in 11 beta-HSD1 occurred before animals developed obesity or overt features of the metabolic syndrome. In contrast to rodents, in utero dexamethasone exposure did not alter glucocorticoid receptor expression in metabolic tissues in marmosets. CONCLUSIONS-These data suggest that long-term upregulation of 11 beta-HSD1 in metabolically active tissues may follow prenatal "stress" hormone exposure and indicates a novel mechanism for fetal origins of adult obesity and the metabolic syndrome. Diabetes 58:2873-2879, 2009
引用
收藏
页码:2873 / 2879
页数:7
相关论文
共 50 条
  • [1] Type 2 diabetes and metabolic syndrome are associated with increased expression of 11β-hydroxysteroid dehydrogenase 1 in obese subjects
    L Alberti
    A Girola
    L Gilardini
    A Conti
    S Cattaldo
    G Micheletto
    C Invitti
    International Journal of Obesity, 2007, 31 : 1826 - 1831
  • [2] Type 2 diabetes and metabolic syndrome are associated with increased expression of 11β-hydroxysteroid dehydrogenase 1 in obese subjects
    Alberti, L.
    Girola, A.
    Gilardini, L.
    Conti, A.
    Cattaldo, S.
    Micheletto, G.
    Invitti, C.
    INTERNATIONAL JOURNAL OF OBESITY, 2007, 31 (12) : 1826 - 1831
  • [3] Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects
    Luisella, Alberti
    Girola, Andrea
    Gilardini, Luisa
    Conti, Antonio
    Micheletto, Giancarlo
    Invitti, Cecilia
    INTERNATIONAL JOURNAL OF OBESITY, 2007, 31 : S88 - S88
  • [4] 11β-Hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome
    Wake, DJ
    Walker, BR
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2004, 215 (1-2) : 45 - 54
  • [5] 11β-Hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome
    Schnackenberg, Christine G.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2008, 9 (03) : 295 - 300
  • [6] Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome
    Wang, MH
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2006, 7 (04) : 319 - 323
  • [7] 11 β-Hydroxysteroid dehydrogenase type 1: potential therapeutic target for metabolic syndrome
    Amit Joharapurkar
    Nirav Dhanesha
    Gaurang Shah
    Rajendra Kharul
    Mukul Jain
    Pharmacological Reports, 2012, 64 : 1055 - 1065
  • [8] 11β-Hydroxysteroid dehydrogenase type 1: potential therapeutic target for metabolic syndrome
    Joharapurkar, Amit
    Dhanesha, Nirav
    Shah, Gaurang
    Kharul, Rajendra
    Jain, Mukul
    PHARMACOLOGICAL REPORTS, 2012, 64 (05) : 1055 - 1065
  • [9] 11β-Hydroxysteroid dehydrogenase type 1 as a therapeutic target in metabolic syndrome and beyond
    Walker, Brian R.
    Seckl, Jonathan R.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231
  • [10] Increased expression of 11β-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes
    Abdallah, BM
    Beck-Nielsen, H
    Gaster, M
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2005, 35 (10) : 627 - 634